Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine (Trivalent, Seasonal, Active Ingredient Content: 15 μg HA/Strain/0.5 mL) in Adults and Elderly Persons

NCT01404182 Phase 4 COMPLETED

The purpose of this study is to determine the immunogenicity and tolerability of Fluval AB trivalent influenza vaccine in adults and elderly people.

Details

Lead sponsor	Fluart Innovative Vaccine Ltd, Hungary
Phase	Phase 4
Status	COMPLETED
Enrolment	121
Start date	2011-07
Completion	2011-08

Conditions

• Influenza

Interventions

• Vaccination with Fluval AB influenza vaccine

Primary outcomes

• Post vaccination HI antibody titer — 21-28 days following vaccination

Countries

Hungary